Recent Updates
Recently added Catalysts

NUC-7738

Phase 1

Advanced Cancer | Small molecule | Oncology |NuCana plc|Last Updated: Jan 12, 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

CONTROLLEDDMC
Total Trials1
Total Enrollment135

FDA Designations

No designations recorded

Clinical trial landscape

NUC-7738 · 1 trial · 4 indications

Phase 1 1
NCT03829254A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and LymphomaAdvanced Cancer
RECRUITING135 Analytics
PHASE1RECRUITING
A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma
Advanced Cancer
NCT03829254135
Unlock trial analytics

Study Endpoints

Primary Endpoints

Number of patients with dose-limiting toxicities
From the date of consent until 30 days after the last dose of NUC-7738 administered

Phase I: Safety and tolerability of NUC-7738 in patients with advanced solid tumours

Number of patients with treatment-emergent adverse events (CTCAE v5.0)
From the date of consent until 30 days after the last dose of NUC-7738 administered

Phase I: Safety and tolerability of NUC-7738 in patients with advanced solid tumours

Number of patients with clinically significant laboratory changes (CTCAE v5.0)
From the date of consent until 30 days after the last dose of NUC-7738 administered

Phase I: Safety and tolerability of NUC-7738 in patients with advanced solid tumours

Number of patients with changes in physical exam, vital signs, and serial electrocardiograms.
From the date of consent until 30 days after the last dose of NUC-7738 administered

Phase I: Safety and tolerability of NUC-7738 in patients with advanced solid tumours

MTD for NUC-7738 administered via weekly and fortnightly dosing schedules in patients with advanced solid tumours
Until completion of Phase I (an average of 1 year)

Phase I

Percentage change from baseline in tumour size
Assessed every 8 weeks following Day 1 up to and including Cycle 12 (each cycle is 14 days) in single-agent cohorts and Cycle 8 in combination cohorts (each cycle is 21 days), moving to every 12 weeks until the end of study (up to 22 months)

Phase II: Efficacy (per RECIST v 1.1, iRECIST or Cheson et al, 2007)

Objective response rate (ORR)
Assessed every 8 weeks following Day 1 up to and including Cycle 12 (each cycle is 14 days) in single-agent cohorts and Cycle 8 in combination cohorts (each cycle is 21 days), moving to every 12 weeks until the end of study (up to 22 months)

Phase II: Efficacy (per RECIST v 1.1, iRECIST or Cheson et al, 2007): defined as the number of patients achieving a confirmed response (complete response \[CR\] or partial response \[PR\])

Duration of response (DoR)
Assessed every 8 weeks following Day 1 up to and including Cycle 12 (each cycle is 14 days) in single-agent cohorts and Cycle 8 in combination cohorts (each cycle is 21 days), moving to every 12 weeks until the end of study (up to 22 months)

Phase II: Efficacy (per RECIST v 1.1, iRECIST or Cheson et al, 2007): defined as the time from the time measurement criteria are first met for CR or PR until the first date that recurrence or progressive disease (PD) is objectively documented (responders only)

Disease control rate (DCR)
Assessed every 8 weeks following Day 1 up to and including Cycle 12 (each cycle is 14 days) in single-agent cohorts and Cycle 8 in combination cohorts (each cycle is 21 days), moving to every 12 weeks until the end of study (up to 22 months)

Phase II: Efficacy (per RECIST v 1.1, iRECIST or Cheson et al, 2007): defined as the proportion of patients achieving confirmed response (CR and PR) or stable disease (SD) as the best overall response

Duration of stable disease (DoSD)
Assessed every 8 weeks following Day 1 up to and including Cycle 12 (each cycle is 14 days) in single-agent cohorts and Cycle 8 in combination cohorts (each cycle is 21 days), moving to every 12 weeks until the end of study (up to 22 months)

Phase II: Efficacy (per RECIST v 1.1, iRECIST or Cheson et al, 2007): defined as the time from the time measurement criteria are first met for SD until the first date that recurrence or PD is objectively documented

Progression free survival (PFS)
Assessed every 8 weeks following Day 1 up to and including Cycle 12 (each cycle is 14 days) in single-agent cohorts and Cycle 8 in combination cohorts (each cycle is 21 days), moving to every 12 weeks until the end of study (up to 22 months)

Phase II: Efficacy (per RECIST v 1.1, iRECIST or Cheson et al, 2007): defined as the time from first dose of study treatment until the date of objective disease progression or death

Secondary Endpoints

Phase I: Plasma concentration of NUC-7738 at end of infusion (Cinf)
Samples collected on Days 1, 2, and 3 of Cycle 1 and Days 1 and 2 of Cycle 2 (cycle: 14 days).
Phase I: Maximum observed plasma concentration (Cmax) of NUC-7738, 3'-dA, 3'-deoxyinosine (3'-dI) and alanine phosphate metabolite of NUC-7738
Samples collected on Days 1, 2, and 3 of Cycle 1 and Days 1 and 2 of Cycle 2 (cycle: 14 days).
Phase I: Area under the plasma concentration-time curve (AUC) of NUC-7738, 3'-dA, 3'-deoxyinosine (3'-dI) and alanine phosphate metabolite of NUC-7738
Samples collected on Days 1, 2, and 3 of Cycle 1 and Days 1 and 2 of Cycle 2 (cycle: 14 days).
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelSEQUENTIAL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
NUC-7738EXPERIMENTALNUC-7738 administered by intravenous infusion on a weekly or fortnightly schedule. In the weekly dosing schedule, NUC-7738 is administered on Days 1 and 8 of a 14-day cycle. In the fortnightly dosing schedule, NUC-7738 is administered on Day 1 of a 14-day cycle.
NUC-7738 + pembrolizumabEXPERIMENTALNUC-7738 administered by intravenous infusion on a weekly schedule on Days 1, 8 and 15 of a 21-day cycle. Pembrolizumab administered by intravenous infusion every 3 weeks on Day 1 of a 21-day cycle.

Interventions

NameTypeDescription
NUC-7738DRUGNUC-7738
PembrolizumabDRUGPembrolizumab
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites9

Inclusion Criteria: 1. Provision of signed written informed consent. 2. Solid tumour cohorts only (Phase I and Phase II; excluding NUC-7738 + pembrolizumab cohort): Histologically confirmed diagnosis of an advanced solid tumour with measurable disease as per RECIST v1.1 criteria and/or evaluable di...

Countries:United Kingdom
Unlock Eligibility Criteria

Competitive Landscape -Cancer 5 trials (matched to "Advanced Cancer")

CompanyTickerTrialsLead PhaseDrugs
GE Healthcare Technologies Inc.GEHC1PHASE1GEH200520/ GEH200521- Part A
Zimmer Biomet Holdings, Inc.ZBH1 - Undisclosed
Ascentage Pharma Group International Unsponsored ADRAAPG1PHASE1Olverembatinib
Unlock Competitive Intelligence

Frequently asked questions about NUC-7738

What is NUC-7738 used for?

NUC-7738 is an investigational small molecule being developed for the treatment of advanced cancer, including advanced solid tumors, lymphoma, and melanoma. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.

Who makes NUC-7738?

NUC-7738 is being developed by NuCana plc, a biopharmaceutical company traded on the NASDAQ under the ticker symbol NCNA. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational oncology drug.

What phase is NUC-7738 in?

NUC-7738 is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory agencies such as the FDA. The ongoing Phase 1 trial is recruiting patients to assess safety, pharmacokinetics, and clinical activity.

What clinical trials is NUC-7738 in?

NUC-7738 is being studied in a Phase 1 clinical trial with the identifier NCT03829254. This trial is titled 'A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma' and is recruiting participants in the United Kingdom.

What is the enrollment and design of the NUC-7738 clinical trial?

The Phase 1 trial of NUC-7738 (NCT03829254) has a planned enrollment of 135 participants aged 18 years and older. It is a controlled, open-label study that is not randomized or double-blinded. The trial is actively recruiting patients with advanced cancer, including solid tumors, lymphoma, and melanoma.